Table 3.

Base‐case results

Country	Ferric carboxymaltose	Placebo	Incremental
United Kingdom
Total costs	GBP10 700	GBP10 839	–GBP139
Treatment (intervention)	GBP242	GBP0	GBP242
Background medical management	GBP3694	GBP3268	GBP426
Hospitalisation for HF	GBP3177	GBP3738	–GBP561
Hospitalisation for non‐HF	GBP787	GBP774	GBP13
CV mortality	GBP1831	GBP2006	–GBP175
Adverse events	GBP969	GBP1053	–GBP84
Total LYs	4.21	3.72	0.49
Total QALYs	2.98	2.55	0.43
ICER	–	–	Dominant
United States of America
Total costs	USD67 475	USD70 896	–USD3421
Treatment (intervention)	USD2112	USD0	USD2112
Background medical management	USD8507	USD7508	USD998
Hospitalisation for HF	USD31 141	USD36 564	–USD5422
Hospitalisation for non‐HF	USD9996	USD9809	USD187
CV mortality	USD15 007	USD16 401	–USD1394
Adverse events	USD1036	USD900	USD136
Total LYs	4.27	3.77	0.50
Total QALYs	3.02	2.58	0.44
ICER	–	–	Dominant
Italy
Total costs	EUR26 489	EUR25 939	EUR550
Treatment (intervention)	EUR270	EUR0	EUR270
Background medical management	EUR14 226	EUR12 572	EUR1654
Hospitalisation for HF	EUR7915	EUR9305	–EUR1389
Hospitalisation for non‐HF	EUR1775	EUR1744	EUR31
CV mortality	EUR1522	EUR1666	–EUR144
Adverse events	EUR781	EUR653	EUR128
Total LYs	4.25	3.76	0.49
Total QALYs	3.01	2.57	0.43
ICER	–	–	EUR1269/QALY
Switzerland
Total costs	CHF45 028	CHF47 733	–CHF2705
Treatment (intervention)	CHF379	CHF0	CHF379
Background medical management	CHF5687	CHF5020	CHF667
Hospitalisation for HF	CHF15 563	CHF18 272	–CHF2709
Hospitalisation for non‐HF	CHF544	CHF5734	CHF110
CV mortality	CHF15 226	CHF16 638	–CHF1412
Adverse events	CHF2330	CHF2070	CHF260
Total LYs	4.28	3.78	0.50
Total QALYs	3.03	2.59	0.44
ICER	–	–	Dominant

CV, cardiovascular; HF, heart failure; ICER, incremental cost‐effectiveness ratio; LY, life‐year; QALY, quality‐adjusted life‐year.